Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCRNASDAQ:IRONNASDAQ:SDGRNASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$31.49-1.7%$29.12$23.15▼$49.05$1.58B0.75390,459 shs1.05 million shsIRONDisc Medicine$45.12-1.7%$45.33$30.82▼$68.73$1.56B0.77346,061 shs274,276 shsSDGRSchrödinger$21.52+0.1%$22.72$16.60▼$28.47$1.57B1.84864,033 shs1.02 million shsZYBTZhengye Biotechnology$8.80+2.8%$7.93$3.50▼$14.30$415.06MN/A362,551 shs881,177 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore-1.72%-0.54%+2.87%+6.46%-31.99%IRONDisc Medicine-1.66%-7.71%-2.25%-17.21%+30.18%SDGRSchrödinger+0.09%+4.92%-16.43%-3.28%-2.67%ZYBTZhengye Biotechnology+2.80%-1.01%-37.81%+102.76%+879,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCRImmunocore2.9734 of 5 stars4.30.00.00.03.64.20.0IRONDisc Medicine2.3051 of 5 stars3.51.00.00.03.92.50.0SDGRSchrödinger2.2263 of 5 stars3.51.00.00.02.62.50.6ZYBTZhengye BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.55Moderate Buy$58.8987.01% UpsideIRONDisc Medicine 3.09Buy$98.80118.97% UpsideSDGRSchrödinger 3.00Buy$32.8052.42% UpsideZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZYBT, IMCR, IRON, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.004/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/12/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.003/12/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.003/7/2025IMCRImmunocoreMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight$35.00 ➝ $35.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$333.58M4.73N/AN/A$7.42 per share4.24IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ASDGRSchrödinger$230.49M6.82$0.58 per share37.42$7.60 per share2.83ZYBTZhengye Biotechnology$189.75M2.19N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/14/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%8/14/2025 (Estimated)SDGRSchrödinger$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)ZYBTZhengye BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ALatest ZYBT, IMCR, IRON, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.033.783.76IRONDisc MedicineN/A19.3619.36SDGRSchrödingerN/A4.114.11ZYBTZhengye BiotechnologyN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%IRONDisc Medicine83.70%SDGRSchrödinger79.05%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%IRONDisc Medicine4.24%SDGRSchrödinger8.60%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.07 million45.48 millionOptionableIRONDisc Medicine3034.63 million28.50 millionNot OptionableSDGRSchrödinger79073.04 million66.59 millionOptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AZYBT, IMCR, IRON, and SDGR HeadlinesRecent News About These CompaniesZhengye Biotechnology faces NASDAQ compliance issueMay 24, 2025 | investing.comZhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing RequirementsMay 23, 2025 | quiverquant.comZhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-FMay 23, 2025 | globenewswire.comZhengye Biotechnology (NASDAQ:ZYBT) Trading Up 13.5% - What's Next?May 14, 2025 | marketbeat.comZhengye Biotechnology (NASDAQ:ZYBT) Stock Price Down 7.2% - Here's What HappenedMay 7, 2025 | marketbeat.comShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYBT, IMCR, IRON, and SDGR Company DescriptionsImmunocore NASDAQ:IMCR$31.49 -0.55 (-1.72%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$31.50 +0.01 (+0.02%) As of 05/28/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Disc Medicine NASDAQ:IRON$45.12 -0.76 (-1.66%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$45.16 +0.05 (+0.10%) As of 05/28/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Schrödinger NASDAQ:SDGR$21.52 +0.02 (+0.09%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$22.26 +0.73 (+3.42%) As of 06:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Zhengye Biotechnology NASDAQ:ZYBT$8.80 +0.24 (+2.80%) As of 05/28/2025 04:00 PM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
